Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: A double-blind placebo-controlled study

Phytotherapy Research

Volumn 11, Issue 7, 1997, Pages 508-511

  Palevitch, D ^a   Earon, G ^b   Carasso, R ^c  

^a Newe Yaár Research Center   (Israel)

^b Private Clinic   (Israel)

^c HILLEL YAFFE MEDICAL CENTER   (Israel)

Author keywords

Double blind placebo controlled study; Feverfew; Headache; Migraine; Parthenolide; Tanacetum parthenium

Indexed keywords

PLACEBO;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TANACETUM PARTHENIUM;

EID: 0030730195     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1573(199711)11:7<508::AID-PTR153>3.0.CO;2-H     Document Type: Article

References (18)

1. Abad, M. J., Bermejo, P., and Villar, A. (1995). An approach to the genus Tanacetum L. (Composites): Phytochemical and pharmacological review. Phytother. Res. 9, 79-92.
2. Anderson, D., Jenkinson, P. C., Dewdney, R. S., Blowers, S. D., Johnson, E. S., and Kadam, N. P. (1988). Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity patients: A comparison of chronic feverfew users and matched non-users. Human Toxicol. 7, 145-152.
3. Awang, D. V. C. (1993). Feverfew fever. A headache for the consumer. HerbalGram 29, 34-36, 66.
4. Awang, D. V. C., Dawson, B. A., and Kindack, D. G. (1991). Parthenolide content of feverfew (Tanacetum parthenium) assessed by HPLC and H-NMR spectroscopy. J. Nat. Prod. 54, 1516-1521.
5. Banthorpe, D. V., Brown, G. D., Janes, J. F., and Marr, I. M. (1990). Parthenolide and other volatiles in the flowerheads of Tanacetum parthenium (L.) Schultz Bip. Flavour Fragrance J. 5, 183-185.
6. Berry, M. I. (1984). Feverfew faces the future. Pharm. J. 611-614.
7. Heptinstall, S., Awang, D. V. C., Dawson, B. A., Kindack, D., Knight, D. W., and May, J. (1992). Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products. J. Pharm. Pharmacol. 44, 391-395.
8. Heptinstall, S., White, A., Williamson, L., and Mitchell, J. R. A. (1985). Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet 1, 1071-1074.
9. Hobbs, C. (1989). Feverfew, Tanacetum parthenium. A review. HerbalGram 26, 26-35, 47.
10. Johnson, E. S. (1984). Feverfew: A Traditional Herbal Remedy for Migraine and Arthritis. Sheldon Press, London.
11. Johnson, E. S., Kadam, N. P., Hylands, D. M., and Hylands, P. J. (1985). Efficacy of feverfew as prophylactic treatment of migraine. Br. Med. J. 291, 569-573.
12. Jone, B., and Kenward, M. G. (Eds). (1989). Design and analysis of cross-over trials. Monographs and Statistics and Applied Probability 34. Chapman & Hall, London.
13. Laurinaitis, G. (1995). Headaches vascular and non-vascular. Aust. J. Med. Herbalism 7, 69-78.
14. Lette, C. (1992). Tanacetum parthenium. Aust. J. Med. Herbalism 4, 79-85.
15. Makheja, A. N., and Bailey, J. M. (1982). A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins, Leukotrienes Med. 8, 653-660.
16. Murphy, J. J., Heptinstall, S., and Mitchell, J. R. A. (1988). Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet, 189-192.
17. Peatfield, R. (1988). Drugs and the treatment of migraine. Trends Pharmacol. Sci. 9, 141-145.
18. Pugh, W. J., and Sambo, K. (1988). Prostaglandin synthetase inhibitors in feverfew. J. Pharm. Pharmacol. 40, 743-745.